GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 24, 2024 16:30 ET
|
GeneDx Holdings Corp.
STAMFORD, Conn., Jan. 24, 2024 (GLOBE NEWSWIRE) -- GeneDx, a leader in delivering improved health outcomes through genomic and clinical insights, today announced that, effective as of January 23,...
GeneDx Announces Preliminary 2023 Financial Results
January 08, 2024 08:55 ET
|
GeneDx Holdings Corp.
Expects to exceed revised 2023 revenue guidance with fourth quarter 2023 revenue from continuing operations of more than $57M.
GeneDx Presents New Data at the American Epilepsy Society Annual Meeting Demonstrating That Exome Sequencing Outperforms Multi-Gene Panels for Patients with Epilepsy
December 01, 2023 08:30 ET
|
GeneDx Holdings Corp.
STAMFORD, Conn., Dec. 01, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced new data to be...
GeneDx to Participate in 6th Annual Evercore ISI HealthCONx Conference
November 28, 2023 16:05 ET
|
GeneDx Holdings Corp.
GeneDx company management will participate in the 6th Annual Evercore ISI HealthCONx Conference.
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 20, 2023 16:05 ET
|
GeneDx Holdings Corp.
STAMFORD, Conn., Nov. 20, 2023 (GLOBE NEWSWIRE) -- GeneDx, a leader in delivering improved health outcomes through genomic and clinical insights, today announced that, effective as of November 17,...
GeneDx Reports Third Quarter 2023 Financial Results and Business Highlights
October 30, 2023 16:05 ET
|
GeneDx Holdings Corp.
Reported total revenue of $53M with more than 40% year-over-year growth of exome and genome test revenue Expanded gross margins to 48% in continuing operations and delivered 52% year-over-year...
GeneDx to Report Third Quarter 2023 Financial Results on Monday, October 30, 2023
October 09, 2023 16:05 ET
|
GeneDx Holdings Corp.
STAMFORD, Conn., Oct. 09, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will release...
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 22, 2023 16:05 ET
|
GeneDx Holdings Corp.
STAMFORD, Conn., Sept. 22, 2023 (GLOBE NEWSWIRE) -- GeneDx, a leader in delivering improved health outcomes through genomic and clinical insights, today announced that, effective as of October 1,...
GeneDx Announces Evolution of Executive Leadership Team
September 11, 2023 08:00 ET
|
GeneDx Holdings Corp.
STAMFORD, Conn., Sept. 11, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS) a leader in delivering improved health outcomes through genomic and clinical insights, today announced the expansion and...
GeneDx Announces Industry-Leading Accomplishment of 500,000 Clinical Exomes Sequenced
September 06, 2023 08:00 ET
|
GeneDx Holdings Corp.
STAMFORD, Conn., Sept. 06, 2023 (GLOBE NEWSWIRE) -- GeneDx, a leader in delivering improved health outcomes through genomic and clinical insights, today announced a monumental accomplishment in its...